Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 1753.

https://doi.org/10.1182/blood-2019-124550

Published: 2019

Journal Articles

Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Cherrie Huang, Kenta Mukaihara, MD PhD, Shrikanta Chattopadhyay, MBBS, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 3108.

https://doi.org/10.1182/blood-2019-131906

Published: 2019

Journal Articles

Cytochromes P450 and Glutathione S-Transferases Polymorphisms: Can They Predict Efficacy of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia?

Samina N. Mukry, PhD, Aneeta Shahni, BS, Uzma Zaidi, FCPS, Tahir S. Shamsi, MBBS,FRCPath

Blood (2019) 134 (Supplement_1): 5920.

https://doi.org/10.1182/blood-2019-129655

Published: 2019

Journal Articles

Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

Dongwoo Kang, PhD, Julie Passarell, MA, Malaz A Abutarif, PhD, Jeanne Mendell, PhD MPH, Ophelia Yin, PhD

Blood (2019) 134 (Supplement_1): 1263.

https://doi.org/10.1182/blood-2019-122582

Published: 2019

Journal Articles

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Vittorio Ruggero Zilioli, Periana Minga, Lara Crucitti, Erika Meli, Monica Luigia Torretta, Anna Esposito, Chiara Rusconi, Roberto Cairoli

Blood (2018) 132 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2018-99-116543

Published: 2018

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cristina Panaroni, PhD, Keertik Fulzele, PhD, Rosemary Soucy, Ka Tat Siu, PhD, Kenta Mukaihara, MD PhD, Cherrie Huang, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2018-99-118482

Published: 2018

Journal Articles

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Ruth Meier, Gabriele Greve, Christoph Niemöller, Heiko Becker, Tobias Ma, Ralitsa Langova, Björn Grüning, Lars Feuerbach, Daniel B. Lipka, Justus Duyster, Prof., Benedikt Brors, Christoph Plass, Michael Lübbert

Blood (2018) 132 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2018-99-113450

Published: 2018

Journal Articles

Microenvironment Induced Myelophthisis Caused By CYP26 Deficiency

Laura Palau, MD, Jessica M. Synder, Traci Beth Topping, Cathryn Hogarth, Nina Isoherranen, Gabriel Ghiaur, MD PhD

Blood (2018) 132 (Supplement 1): 1297.

https://doi.org/10.1182/blood-2018-99-115331

Published: 2018

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

Yu-Ting Chang, MS, Daniela Hernandez, MD, Gabriel Ghiaur, MD PhD, Mark J. Levis, MD, Richard J. Jones, MD

Blood (2017) 130 (Supplement 1): 2519.

https://doi.org/10.1182/blood.V130.Suppl_1.2519.2519

Published: 2017

Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC

Blood (2017) 130 (Suppl_1): 980.

https://doi.org/10.1182/blood.V130.Suppl_1.980.980

Published: 2017

Journal Articles

Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

Jai N Patel, PharmD, Issam Hamadeh, BS, Qing Zhang, PhD, Taylor Brown, BS, MS, Nury M Steuerwald, PhD, Alicia Hamilton, Lawrence J Druhan, PhD, Jiaxian He, MS, James T Symanowski, PhD, Mohammed J Hussain, MD, Jigar Trivedi, MSc, PharmD, Michael Richard Grunwald, MD, Nilanjan Ghosh, MD PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD

Blood (2017) 130 (Supplement 1): 3215.

https://doi.org/10.1182/blood.V130.Suppl_1.3215.3215

Published: 2017

Journal Articles

Vitamin D Relation to Busulphan in Pediatrics Undergoing Hematopoietic Stem Cell Transplantation

Fadwa Benkessou, MSc, Moustapha Hassan, PhD, Ibrahim El serafi, PhD, Ahmed El serafi, PhD, Wenyi Zheng, Manuchehr Abedi-Valugerdi, PhD, Jonas Mattsson, MD PhD, Martin Höglund, MD PhD, Karin Mellgren, MD PhD

Blood (2017) 130 (Supplement 1): 5481.

https://doi.org/10.1182/blood.V130.Suppl_1.5481.5481

Published: 2017

Journal Articles

Explore: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyrias (AHP) with Recurrent Attacks

Blood (2017) 130 (Supplement 1): 2211.

https://doi.org/10.1182/blood.V130.Suppl_1.2211.2211

Published: 2017

Journal Articles

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

XiaoWen Tang, MD, Honglan Qu, Dandan Guo, Ting Xu, Haiping Dai, Zheng Li, Jia Yin, Xiaopeng Tian, Danqing Guo, Yang Xu, MD PhD, Xiaming Zhu, Liyan Miao, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 4827.

https://doi.org/10.1182/blood.V130.Suppl_1.4827.4827

Published: 2017

Journal Articles

CYP2C19 Genotype-Guided Dosing and Voriconazole Concentrations in Hematopoietic Stem Cell Transplant Patients (HSCT) Receiving Antifungal Prophylaxis

Jai N Patel, PharmD, Myra M Robinson, Issam Hamadeh, PharmD, Zainab Shahid, MD, James T Symanowski, PhD, Dragos Plesca, PharmD, PhD, Margaret Croom, PharmD, Jigar Trivedi, MSc, PharmD, Nury M. Steuerwald, PhD, Belinda R. Avalos, MD, Edward A. Copelan, MD FACP

Blood (2016) 128 (22): 3416.

https://doi.org/10.1182/blood.V128.22.3416.3416

Published: 2016

Journal Articles

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Blood (2016) 128 (22): 4399.

https://doi.org/10.1182/blood.V128.22.4399.4399

Published: 2016

Journal Articles

Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Mark J. Levis, MD PhD, Jorge E. Cortes, MD, Guy M. Gammon, MBBS, MRCP, Denise Trone, Dongwoo Kang, Jianke Li

Blood (2016) 128 (22): 4042.

https://doi.org/10.1182/blood.V128.22.4042.4042

Published: 2016

Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD

Blood (2016) 128 (22): 3964.

https://doi.org/10.1182/blood.V128.22.3964.3964

Published: 2016

NARROW

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cytochromes P450 and Glutathione S-Transferases Polymorphisms: Can They Predict Efficacy of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia?

Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Microenvironment Induced Myelophthisis Caused By CYP26 Deficiency

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

Vitamin D Relation to Busulphan in Pediatrics Undergoing Hematopoietic Stem Cell Transplantation

Explore: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyrias (AHP) with Recurrent Attacks

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

CYP2C19 Genotype-Guided Dosing and Voriconazole Concentrations in Hematopoietic Stem Cell Transplant Patients (HSCT) Receiving Antifungal Prophylaxis

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only